PillRx only · Tablet, Film Coated · Oral
Empagliflozin And Linagliptin
Brands: Glyxambi · Empagliflozin + Linagliptin
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US2 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 6 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$11.226
Latest avg · Jul 22, 2026
+0%
Since Jan 1, 2026
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
3.5K
Rx · 2026 Q1
154K
Units dispensed
-17%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | unknown | 6 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Mar 15, 2021RECALLRecall (Class II): Glyxambi (empagliflozin and linagliptin) Tablets 25 mg/5 mg 30 tablets Rx only NDC 0597-0164-30 Dist. by: Boehringer In…
CGMP Deviations: Intermittent exposure to temperature excursion during storage. — Recalling firm: Cardinal Health Inc. — FL, GA, SC